Eli Lilly and CompanyLLYNYSE
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank15
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P15
Within normal range
vs 5Y Ago
-133.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -63.51% |
| Q3 2025 | 186.24% |
| Q2 2025 | 85.33% |
| Q1 2025 | -32.67% |
| Q4 2024 | -33.35% |
| Q3 2024 | 153.16% |
| Q2 2024 | 25.75% |
| Q1 2024 | 473.84% |
| Q4 2023 | -114.25% |
| Q3 2023 | 246.49% |
| Q2 2023 | -63.49% |
| Q1 2023 | 9.55% |
| Q4 2022 | -28.74% |
| Q3 2022 | 87.33% |
| Q2 2022 | -53.10% |
| Q1 2022 | 17.00% |
| Q4 2021 | 32.20% |
| Q3 2021 | -8.12% |
| Q2 2021 | 4.60% |
| Q1 2021 | -6.49% |
| Q4 2020 | 0.48% |
| Q3 2020 | -27.60% |
| Q2 2020 | 552.56% |
| Q1 2020 | -80.53% |
| Q4 2019 | 30.04% |
| Q3 2019 | 43.61% |
| Q2 2019 | 237.78% |
| Q1 2019 | -78.51% |
| Q4 2018 | -31.72% |
| Q3 2018 | 39.82% |
| Q2 2018 | 247.65% |
| Q1 2018 | -74.96% |
| Q4 2017 | -7.31% |
| Q3 2017 | 13.93% |
| Q2 2017 | 385.76% |
| Q1 2017 | -83.94% |
| Q4 2016 | 27.59% |
| Q3 2016 | 18.35% |
| Q2 2016 | 739.84% |
| Q1 2016 | -127.24% |